Literature DB >> 12474997

The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study.

N F Kalkers1, F Barkhof, E Bergers, R van Schijndel, C H Polman.   

Abstract

Progressive axonal loss is the most likely pathologic correlate of irreversible neurologic impairment in primary progressive multiple sclerosis. In a run-in versus treatment trial, we show that the neuroprotective agent riluzole seems to reduce the rate of cervical cord atrophy and the development of hypointense T1 brain lesions on magnetic resonance imaging.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12474997     DOI： 10.1191/1352458502ms849xx

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


  33 in total

Review 1.  MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials.

Authors:  Frederik Barkhof; Jack H Simon; Franz Fazekas; Marco Rovaris; Ludwig Kappos; Nicola de Stefano; Chris H Polman; John Petkau; Ernst W Radue; Maria P Sormani; David K Li; Paul O'Connor; Xavier Montalban; David H Miller; Massimo Filippi
Journal:  Nat Rev Neurol       Date:  2011-12-06       Impact factor: 42.937

Review 2.  Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future?

Authors:  Ludwig Kappos; Jens Kuhle; Achim Gass; Lutz Achtnichts; Ernst-Wilhelm Radue
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

Review 3.  Neuroprotection and neuroregeneration in multiple sclerosis.

Authors:  Martin Stangel
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

4.  Automatic magnetic resonance spinal cord segmentation with topology constraints for variable fields of view.

Authors:  Min Chen; Aaron Carass; Jiwon Oh; Govind Nair; Dzung L Pham; Daniel S Reich; Jerry L Prince
Journal:  Neuroimage       Date:  2013-08-06       Impact factor: 6.556

Review 5.  Secondary Progressive Multiple Sclerosis: Definition and Measurement.

Authors:  Domenico Plantone; Floriana De Angelis; Anisha Doshi; Jeremy Chataway
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

Review 6.  Spinal cord MRI in multiple sclerosis--diagnostic, prognostic and clinical value.

Authors:  Hugh Kearney; David H Miller; Olga Ciccarelli
Journal:  Nat Rev Neurol       Date:  2015-05-26       Impact factor: 42.937

Review 7.  Assessing Repair in Multiple Sclerosis: Outcomes for Phase II Clinical Trials.

Authors:  Maria Pia Sormani; Matteo Pardini
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 8.  Translational research in neurology and neuroscience 2010: multiple sclerosis.

Authors:  Olaf Stüve; Bernd C Kieseier; Bernhard Hemmer; Hans-Peter Hartung; Amer Awad; Elliot M Frohman; Benjamin M Greenberg; Michael K Racke; Scott S Zamvil; J Theodore Phillips; Ralf Gold; Andrew Chan; Uwe Zettl; Ron Milo; Ellen Marder; Omar Khan; Todd N Eagar
Journal:  Arch Neurol       Date:  2010-07-12

Review 9.  Imaging as an Outcome Measure in Multiple Sclerosis.

Authors:  Daniel Ontaneda; Robert J Fox
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 10.  [Multiple sclerosis: potential therapeutic options and update of ongoing studies].

Authors:  H Wiendl; H C Lehmann; R Hohlfeld; H-P Hartung; B C Kieseier
Journal:  Nervenarzt       Date:  2004-06       Impact factor: 1.214
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.